Skip to content
OpenCapital
Get started

CRISPR Therapeutics CRSP Payments to Acquire Equity Securities, FV-NI

Payments to Acquire Equity Securities, FV-NI at other companies

TEC
Bio-TechneTECH
——

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%
Enterprise value$5.69B+69.8%
P/S1,298.3×+1,208×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireEquitySecuritiesFvNi.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's payments to acquire equity securities, fv-ni.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's payments to acquire equity securities, FV-NI?
CRISPR Therapeutics (CRSP) reported payments to acquire equity securities, FV-NI of $4.62M in Q1 2026.
How has CRISPR Therapeutics's payments to acquire equity securities, FV-NI changed year-over-year?
CRISPR Therapeutics's payments to acquire equity securities, FV-NI decreased by 7.7% year-over-year, from $5M to $4.62M.